The Vanguard Group 13D and 13G filings for Recursion Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-12 4:57 pm Unchanged |
2024-09-30 | 13G | Recursion Pharmaceuticals, Inc. RXRX |
The Vanguard Group | 24,272,798 8.820% |
0 (Unchanged) |
Filing |
| 2024-11-04 1:27 pm Purchase |
2024-09-30 | 13G | Recursion Pharmaceuticals, Inc. RXRX |
The Vanguard Group | 24,272,798 8.820% |
8,607,588 (+54.95%) |
Filing |
| 2024-02-13 5:12 pm Purchase |
2023-12-29 | 13G | Recursion Pharmaceuticals, Inc. RXRX |
The Vanguard Group | 15,665,210 7.520% |
5,607,847 (+55.76%) |
Filing |
| 2023-02-09 11:30 am Purchase |
2022-12-30 | 13G | Recursion Pharmaceuticals, Inc. RXRX |
The Vanguard Group | 10,057,363 5.540% |
10,057,363 (New Position) |
Filing |